Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04829773 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects
A Phase 1 study of Fibrodysplasia Ossificans Progressiva, sponsored by Clementia Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT04829773 is a Phase 1 study of Fibrodysplasia Ossificans Progressiva that has completed, run by Clementia Pharmaceuticals. The registered enrollment target is 48 participants, below the 92-participant average among 4 other Fibrodysplasia Ossificans Progressiva trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04829773, a Phase 1 study of Fibrodysplasia Ossificans Progressiva, has completed, sponsored by Clementia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Study to evaluate the effect of food and the effect of swallowing capsule whole versus sprinkling on apple sauce on the pharmacokinetics (PK)/bioavailability of palovarotene, and evaluate the effect of palovarotene on the PK of the CYP3A4 substrate midazolam.
Conditions Studied
Interventions
- DRUG midazolam
- DRUG Palovarotene
Study Locations (1)
Massachusetts
- Cambridge Ipsen US - Cambridge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-01-03 |
| Est. Completion | 2019-03-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04829773
The ClinicalTrials.gov registry entry for NCT04829773 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 92-participant average among 4 other Fibrodysplasia Ossificans Progressiva trials with a reported enrollment target (48% lower). The listed sponsor is Clementia Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fibrodysplasia Ossificans Progressiva appearing as the primary indexed condition, and to 2 interventions - of which midazolam is the first listed.
NCT04829773 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04829773 about?
NCT04829773 is a clinical study titled "Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects". Study to evaluate the effect of food and the effect of swallowing capsule whole versus sprinkling on apple sauce on the pharmacokinetics (PK)/bioavailability of palovarotene, and evaluate the effect of palovarotene on the PK of the CYP3A4 substrate midazolam.
What is the current status of trial NCT04829773?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2019-01-03. Estimated completion is 2019-03-29.
What conditions does trial NCT04829773 study?
This clinical trial studies the following conditions: Fibrodysplasia Ossificans Progressiva.
What interventions are being tested in trial NCT04829773?
The interventions under investigation include: midazolam (DRUG), Palovarotene (DRUG).
Who is sponsoring clinical trial NCT04829773?
This trial is sponsored by Clementia Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04829773 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibrodysplasia Ossificans Progressiva
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
RECRUITING
-
A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.